WO2000040604A3 - METHODS AND COMPOSITIONS FOR MODULATING CYTOKINE RELEASE BY αEβ7-EXPRESSING CELLS - Google Patents
METHODS AND COMPOSITIONS FOR MODULATING CYTOKINE RELEASE BY αEβ7-EXPRESSING CELLS Download PDFInfo
- Publication number
- WO2000040604A3 WO2000040604A3 PCT/US1999/030992 US9930992W WO0040604A3 WO 2000040604 A3 WO2000040604 A3 WO 2000040604A3 US 9930992 W US9930992 W US 9930992W WO 0040604 A3 WO0040604 A3 WO 0040604A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- αeβ7
- methods
- compositions
- expressing cells
- cytokine release
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/53—Colony-stimulating factor [CSF]
- G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU23904/00A AU2390400A (en) | 1999-01-08 | 1999-12-28 | Methods and compositions for modulating cytokine release by alphaebeta7-expressing cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11505599P | 1999-01-08 | 1999-01-08 | |
US60/115,055 | 1999-01-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000040604A2 WO2000040604A2 (en) | 2000-07-13 |
WO2000040604A3 true WO2000040604A3 (en) | 2000-11-09 |
Family
ID=22359050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/030992 WO2000040604A2 (en) | 1999-01-08 | 1999-12-28 | METHODS AND COMPOSITIONS FOR MODULATING CYTOKINE RELEASE BY αEβ7-EXPRESSING CELLS |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2390400A (en) |
WO (1) | WO2000040604A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710532A (en) * | 2004-09-03 | 2015-06-17 | 健泰科生物技术公司 | Humanized anti-beta7 antagonists and uses therefor |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5594120A (en) * | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
US5610281A (en) * | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
WO1997025423A1 (en) * | 1996-01-05 | 1997-07-17 | Icos Corporation | Cytoplasmic modulators of integrin binding |
WO1998025144A1 (en) * | 1996-12-06 | 1998-06-11 | The Scripps Research Institute | Methods and cell lines for identification of regulators of integrin activation and compositions identified thereby |
JPH10218790A (en) * | 1997-02-10 | 1998-08-18 | Kazuo Tsubota | Adhesion inhibitor of secretory gland cell to lymphocyte |
-
1999
- 1999-12-28 AU AU23904/00A patent/AU2390400A/en not_active Abandoned
- 1999-12-28 WO PCT/US1999/030992 patent/WO2000040604A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5594120A (en) * | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
US5610281A (en) * | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
WO1997025423A1 (en) * | 1996-01-05 | 1997-07-17 | Icos Corporation | Cytoplasmic modulators of integrin binding |
WO1998025144A1 (en) * | 1996-12-06 | 1998-06-11 | The Scripps Research Institute | Methods and cell lines for identification of regulators of integrin activation and compositions identified thereby |
JPH10218790A (en) * | 1997-02-10 | 1998-08-18 | Kazuo Tsubota | Adhesion inhibitor of secretory gland cell to lymphocyte |
Non-Patent Citations (8)
Title |
---|
B LUDVIKSSON ET AL: "Administration of mAb against alphaEbeta7 prevents and ameliorates immunization-induced colitis in IL-2-/- mice", JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 162, no. 8, 15 April 1999 (1999-04-15), pages 4975 - 4982-4982, XP002129086, ISSN: 0022-1767 * |
C JORGENSEN ET AL: "Inhibition of human mucosal lymphocytes migration in rheumatoid synovium engrafted in SCID mice by antibodies against LFA-1 and alphaEbeta7 adhesion molecules", ARTHRITIS AND RHEUMATISM,US,LIPPINCOTT, PHILADELPHIA, vol. 37, no. 9, SUPPL, September 1994 (1994-09-01), pages 5220, XP002129083, ISSN: 0004-3591 * |
CEPEK K.L. ET AL.: "Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha-E-beta-7 integrin", NATURE, vol. 372, 1994, pages 190 - 193, XP002137720 * |
JORGENSEN C ET AL: "Overexpression of integrin alpha-E-beta-7 on synovial fluid lymphocytes in rheumatoid arthritis and its regulation by sulfasalazine, sulfapyridine, 5-ASA and methotrexate", ARTHRITIS AND RHEUMATISM,US,LIPPINCOTT, PHILADELPHIA, vol. 37, no. 9, SUPPL, 1994, pages S255, XP002138709, ISSN: 0004-3591 * |
PANG M ET AL: "UP-REGULATION OF ALPHAEBETA7, A NOVEL INTEGRIN ADHESION MOLECULE, ON T CELLS FROM SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH SPECIFIC EPITHELIAL INVOLVEMENT", ARTHRITIS AND RHEUMATISM,US,LIPPINCOTT, PHILADELPHIA, vol. 41, no. 8, August 1998 (1998-08-01), pages 1456 - 1463-1463, XP000867228, ISSN: 0004-3591 * |
PARKER C.M. ET AL.: "A family of beta-7 integrins on human mucosal lymphocytes", PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 1294 - 1298, XP002137721 * |
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 13 30 November 1998 (1998-11-30) * |
RUSSELL G J ET AL: "DISTINCT STRUCTURAL AND FUNCTIONAL EPITOPES OF THE ALPHAE BETA7 INTEGRIN", EUROPEAN JOURNAL OF IMMUNOLOGY,DE,WEINHEIM, vol. 24, 1 November 1994 (1994-11-01), pages 2832 - 2841, XP000672907, ISSN: 0014-2980 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710532A (en) * | 2004-09-03 | 2015-06-17 | 健泰科生物技术公司 | Humanized anti-beta7 antagonists and uses therefor |
CN104710532B (en) * | 2004-09-03 | 2019-01-18 | 健泰科生物技术公司 | The anti-beta 7 antagonists of humanization and its application |
Also Published As
Publication number | Publication date |
---|---|
WO2000040604A2 (en) | 2000-07-13 |
AU2390400A (en) | 2000-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001062942A3 (en) | MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS | |
AU7703400A (en) | Substrates and screening methods for transport proteins | |
WO2006083276A3 (en) | Interferon-alpha polypeptides and conjugates | |
WO2004035603A3 (en) | Erythropoietin receptor binding antibodies | |
WO2005113592A3 (en) | Interferon-alpha polypeptides and conjugates | |
EP1399547A4 (en) | METHODS AND COMPOSITIONS COMPRISING i RENILLA /i GFP | |
EP2290079A3 (en) | Neurotrophic factors | |
WO2009038760A3 (en) | Human gm-csf antigen binding proteins | |
WO2004036189A3 (en) | Methods for separating molecules | |
NO20043257L (en) | Encapsulated binding proteins such as biosensors | |
EP1741713A3 (en) | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | |
WO1999035495A3 (en) | Identification of substances that modify cellular secretory function | |
WO2006116181A3 (en) | Regulatory t cell mediator proteins and uses thereof | |
DK1379671T3 (en) | Methods for culturing circovirus | |
WO2005017205A3 (en) | Nucleic acid mapping using linear analysis | |
EP1967590A3 (en) | Lentiviral packaging constructs | |
AU2334301A (en) | Chemokine receptor binding heterocyclic compounds | |
WO2006087163A3 (en) | Novel in vitro methods for studying receptors recognizing volatile compounds | |
WO2001034824A3 (en) | Methods and compositions comprising renilla gfp | |
WO2004046365A3 (en) | Interferon-alpha polypeptides and conjugates | |
WO2005028497A3 (en) | Receptor binding peptides derived from the sars s protein | |
WO2003029814A3 (en) | Neuropilin/vegf c/vegfr 3 materials and methods | |
WO2001049721A3 (en) | Bacterial genes and proteins that are essential for cell viability and their uses | |
WO2002049625A3 (en) | Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds | |
EP1616882A3 (en) | Apo-2 receptor antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |